Share on StockTwits

Gilead Sciences (NASDAQ:GILD) has received an average recommendation of “Buy” from the thirty-two brokerages that are currently covering the company, AnalystRatings.Net reports. Three investment analysts have rated the stock with a hold rating and twenty-three have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $84.59.

Shares of Gilead Sciences (NASDAQ:GILD) traded up 2.67% on Tuesday, hitting $68.57. 1,893,860 shares of the company’s stock traded hands. Gilead Sciences has a 52 week low of $46.70 and a 52 week high of $84.88. The stock’s 50-day moving average is $75.79 and its 200-day moving average is $73.51. The company has a market cap of $105.5 billion and a price-to-earnings ratio of 36.90.

Gilead Sciences (NASDAQ:GILD) last released its earnings data on Tuesday, February 4th. The company reported $0.55 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.50 by $0.05. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 20.5% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $3.99 earnings per share for the current fiscal year.

In other Gilead Sciences news, Director John Francis Cogan sold 5,000 shares of the stock on the open market in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of $70.55, for a total transaction of $352,750.00. Following the completion of the sale, the director now directly owns 39,542 shares in the company, valued at approximately $2,789,688. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

GILD has been the subject of a number of recent research reports. Analysts at Wells Fargo & Co. reiterated a “buy” rating on shares of Gilead Sciences in a research note on Monday. They now have a $5.79 price target on the stock. Separately, analysts at Nomura raised their price target on shares of Gilead Sciences from $120.00 to $121.00 in a research note on Thursday, April 10th. They now have a “buy” rating on the stock. Finally, analysts at Zacks downgraded shares of Gilead Sciences from an “outperform” rating to a “neutral” rating in a research note on Thursday, April 10th. They now have a $74.00 price target on the stock.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.